Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018144777) CALRETICULIN-MEDIATED CANCER TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/144777 International Application No.: PCT/US2018/016513
Publication Date: 09.08.2018 International Filing Date: 01.02.2018
IPC:
A61K 39/395 (2006.01) ,A61K 35/17 ,A61P 35/00 (2006.01) ,A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
NANT HOLDINGS IP, LLC [US/US]; 9920 Jefferson Boulevard Culver City, California 90232, US
Inventors:
SOON-SHIONG, Patrick; US
Agent:
FESSENMAIER, Martin; US
SHIN, Minyoung; US
Priority Data:
62/453,22901.02.2017US
Title (EN) CALRETICULIN-MEDIATED CANCER TREATMENT
(FR) TRAITEMENT DU CANCER À MÉDIATION PAR CALRÉTICULINE
Abstract:
(EN) Contemplated compositions and methods take advantage of one or more surface markers on cancer stem cell that are associated with self-protection of tumor cells. Such surface markers are specifically targeted to guide a cell-based cancer treatment, and especially hypoxia resistant NK cells and radiotherapeutics directly to the cancer stem cell. In addition, immune suppression can be counteracted using various inhibitors, while immune response may be further augmented using certain immune stimulatory agents.
(FR) Les compositions et les méthodes envisagées selon l'invention tirent profit d'un ou de plusieurs marqueurs de surface sur une cellule souche cancéreuse qui sont associés à l'auto-protection de cellules tumorales. De tels marqueurs de surface sont spécifiquement ciblés pour guider un traitement du cancer à base de cellules, et en particulier des cellules NK résistantes à l'hypoxie et des agents radiothérapeutiques ciblant directement la cellule souche cancéreuse. De plus, la suppression immunitaire peut être neutralisée à l'aide de divers inhibiteurs, tandis que la réponse immunitaire peut être encore accrue à l'aide de certains agents immunostimulateurs.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)